Tumour-related factors and prognosis in breast cancer detected by screening

British Journal of Surgery

Volumn 99, Issue 1, 2012, Pages 78-87

  Olsson, A ^a   Borgquist, S ^a   Butt, S ^a   Zackrisson, S ^a   Landberg, G ^b   Manjer, J ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CCND1 PROTEIN, HUMAN; CYCLIN D1; CYCLINE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; P27 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

AGED; ARTICLE; BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MASS SCREENING; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; SWEDEN;

AGED; BREAST NEOPLASMS; CYCLIN D1; FEMALE; HUMANS; KI-67 ANTIGEN; LOGISTIC MODELS; LYMPHATIC METASTASIS; MASS SCREENING; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 82955190544     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.7757     Document Type: Article

References (38)

1. Pálka I, Kelemen G, Ormándi K, Lázár G, Nyári T, Thurzõ L, et al., Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 2008; 14: 161-167.
2. Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA,. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005; 97: 1195-1203. (Pubitemid 41258225)
3. Joensuu H, Lehtimäki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, et al., Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004; 292: 1064-1073. (Pubitemid 39129196)
4. Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, et al., Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 2008; 98: 1741-1744. (Pubitemid 351748836)
5. Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, et al., Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338-1344.
6. Mook S, Van 't Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, et al., Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 2011; 103: 585-597.
7. Patani N, Mokbel K,. Herceptin and breast cancer: an overview for surgeons. Surg Oncol 2010; 19: 11-21.
8. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, et al., Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005; 58: 611-616. (Pubitemid 40814021)
9. Barzanti F, Dal Susino M, Volpi A, Amadori D, Riccobon A, Scarpi E, et al., Comparison between different cell kinetic variables in human breast cancer. Cell Prolif 2000; 33: 75-89. (Pubitemid 30307236)
10. Dunnwald LK, Rossing MA, Li CI,. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 2007; 9: R6.
11. Kip1. Breast Cancer Res Treat 1998; 52: 29-41. (Pubitemid 29056083)
12. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, et al., Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol 2000; 74: 279-285. (Pubitemid 32126240)
13. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ,. Meeting highlights: updated international consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365. (Pubitemid 46606270)
14. Coqueret O,. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 2003; 13: 65-70. (Pubitemid 36135887)
15. Roy PG, Thompson AM,. Cyclin D1 and breast cancer. Breast 2006; 15: 718-727. (Pubitemid 44774238)
16. Dowsett M, Dunbier AK,. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 2008; 15: 8019-8026.
17. Berglund G, Elmstähl S, Janzon L, Larsson SA,. The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med 1993; 233: 45-51.
18. Manjer J, Carlsson S, Elmståhl S, Gullberg B, Janzon L, Lindstrom M, et al., The Malmö Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev 2001; 10: 489-499. (Pubitemid 34048904)
19. The National Board of Health and Welfare. The Swedish Causes of Death Registry. [accessed 31 December 2008].
20. World Health Organization. [Histological typing of breast tumours. Second edition. Geneva, 1981.] Ann Pathol 1982; 2: 91-105.
21. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
22. Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, et al., HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors. Int J Cancer 2008; 123: 1146-1153.
23. Jönsson P-E, (ed). Bröst Cancer. Astra Zeneca: Södertälje, 2004.
24. Kricker A, Newman B, Gertig DM, Goumas C, Armes J, Armstrong BK,. Why do large breast cancers still present in a population offered screening? Int J Cancer 2008; 123: 2907-2914.
25. Zackrisson S,. Breast Cancer in an Urban Swedish Population. Aspects of Non-attendance, Interval Cancers and Over-diagnosis. Malmö University Hospital, Lund University: Lund, 2006.
26. Matson S, Andersson I, Berglund G, Janzon L, Manjer J,. Nonattendance in mammographic screening: a study of intraurban differences in Malmö, Sweden, 1990-1994. Cancer Detect Prev 2001; 25: 132-137.
27. Zackrisson S, Andersson I, Manjer J, Janzon L,. Non-attendance in breast cancer screening is associated with unfavourable socio-economic circumstances and advanced carcinoma. Int J Cancer 2004; 108: 754-760. (Pubitemid 38076408)
28. Freedman LS, Graubard BI, Schatzkin A,. Statistic validation of intermediate endpoints for chronic diseases. Stat Med 1992; 11: 167-178.
29. Camp RL, Charette LA, Rimm DL,. Validation of tissue microarray technology in breast carcinoma. Lab Invest 2000; 80: 1943-1949. (Pubitemid 32012762)
30. García María F, González-Reyes S, González Luis O, Junquera S, Berdize N, Del Casar José M, et al., Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol 2010; 91: 324-334.
31. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA,. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004; 279: 51 323-51 330.
32. Howell A, Landberg G, Bergh J,. Breast tumour stroma is a prognostic indicator and target for therapy. Breast Cancer Res 2009; 11 (Suppl 3): S16.
33. Yee KO, Connolly CM, Duquette M, Kazerounian S, Washington R, Lawler J,. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res Treat 2009; 114: 85-96.
34. Patani NR, Dwek MV, Douek M,. Predictors of axillary lymph node metastasis in breast cancer: a systematic review. Eur J Surg Oncol 2007; 33: 409-419. (Pubitemid 46591166)
35. Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Butzow R, Holli K, et al., Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 2008; 14: 4103-4110.
36. Duffy SW, Nagtegaal ID, Wallis M, Cafferty F, Houssami N, Warwick J, et al., Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. Am J Epidemiol 2008; 168: 98-104. (Pubitemid 351881896)
37. Lawrence G, Wallis M, Allgood P, Nagtegaal ID, Warwick J, Cafferty FH,. Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat 2009; 116: 179-185.
38. Mahnken JD, Chan W, Freeman DH Jr, Freeman JL,. Reducing the effects of lead-time bias, length bias and over-detection in evaluating screening mammography: a cencored bivariate data approach. Stat Methods Med Res 2008; 17: 643-663.